JPRN-UMIN000026856招募中2 期
Phase 2 study of bevacizumab in a fixed term for glioblastoma - Study of bevacizumab in a fixed term for glioblastoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Evidence of recent haemorrhage on postoperative MRI. (2) Any prior chemotherapy, radiotherapy or immunotherapy (including vaccine therapy) for glioma. (3) Prior radiotherapy to the brain. (4) Uncontrolled hypertension (systolic pressure >= 150, diastolic pressure >= 100). (5)Prior history of hypertensive crisis, or hypertensive encephalopathy. (6)Congestive heart failure (NYHA class III, or greater) (7)History of hemoptysis (Grade 2 or higher in CTCAE v4.0) within 1 month. (8) Coagulopathy (9) Uncontrolled gastrointestinal ulceration. (10) Serious or non-healing wound or traumatic bone fracture. (11) Past history within 6 months, as follows. Unstable angina, acute myocardial infarction, symptomatic cerebral infarction, arterial or venous thrombosis which required medical treatment, digestive tract perforation or abdominal fistula,intra-abdominal abscess, and intracranial abscess (12) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ (13) Pregnancy or lactation, as well as fertile women and men unwilling or unable to use effective means of contraception (14) Allergy to temozolomide, bevacizumab (15) Patients with allergy to gadolinium. (16) Patients registering other clinical trial. (17) Attending physician has determined unsuitable to participate in the study.
研究者
相似试验
已完成
2 期
A phase II study for the efficacy of bevacizumab with paclitaxel and carboplatin in patient with stage IVB, recurrent or persistant cervical cancer.Stage IVB, recurrent or persistant cervical cancerJPRN-UMIN000026063Japan Gynecologic Oncology Group:JGOG70
进行中（未招募）
不适用
Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancerMetastatic or locally recurrent HER2-negative breast cancerMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2009-016062-82-HUSOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP88
已完成
不适用
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancerJPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25
已完成
2 期
Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerChemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000003698Hyogo Cancer Center,Depatrment of Thoracic Oncology45
招募中
2 期
Phase 2 study of Bevacizumab Beyond Progression treatment in patients with advanced non-squamous non-small-cell Lung canceradvanced non-squamous non-small-cell Lung cancerJPRN-UMIN000007854Keio University31